ProNai: Jefferies Global Healthcare Conference 2016 (ProNAi) - Jun 12, 2016 - "Interim Safety"; "Overall, the safety profile of PNT2258 appears acceptable in subjects with PS-01 and ≤3 prior lines of therapy: 33 subjects have discontinued PNT2258 therapy, 65% of subjects experienced one or more Grade 3 or 4 AEs, Most common AEs were fatigue, nausea, pyrexia, anemia, diarrhea, hypotension, and thrombocytopenis, We determined that the most advanced subjects, with PS 2 and/or having received 4 lines of therapy, did not respond to therapy, and experienced higher rates of serious adverse events and Grade 5 events"; "Interim Efficacy"; "PNT2258 showed modest single-agent activity in r/r DLBCL patients"; "All three responses were observed in subjects with PS 0-1 and 3 prior lines of therapy"
P2 data • Diffuse Large B Cell Lymphoma • Non-Hodgkin's Lymphoma • Oncology
|